Key Finding
Herb-partitioned moxibustion significantly upregulated miR-147 and miR-205 expression in experimental Crohn's disease rats, reducing colonic inflammation through downregulation of inflammatory pathways and cytokine production.
Crohn's disease is a chronic inflammatory bowel condition that causes significant digestive problems and discomfort. Researchers in China investigated whether herb-partitioned moxibustion (HPM)—a traditional Chinese medicine technique where heated herbs are placed on acupuncture points—could help treat Crohn's disease by affecting tiny genetic regulators called microRNAs. The study used rats with experimentally induced Crohn's disease to understand how the condition affects these microRNAs and whether HPM could reverse these changes.
The researchers discovered that rats with Crohn's disease had significantly lower levels of two specific microRNAs (miR-147 and miR-205) in their intestinal tissue. These microRNAs normally help control inflammation in the body. When the researchers treated the rats with herb-partitioned moxibustion, they found that this therapy increased the levels of these protective microRNAs back toward normal. This increase appeared to reduce inflammation in the colon and improve the intestinal damage caused by Crohn's disease.
What this means for patients: This study provides scientific evidence for how moxibustion might help manage Crohn's disease at a molecular level. The technique appears to work by restoring the body's natural anti-inflammatory mechanisms rather than just suppressing symptoms. While this research was conducted on animals and human studies are needed, it adds to the growing body of evidence supporting moxibustion as a complementary therapy for inflammatory bowel conditions. If you're considering moxibustion for Crohn's disease, consult with a licensed acupuncturist who has experience treating digestive disorders.
This experimental study investigated the molecular mechanisms underlying herb-partitioned moxibustion (HPM) efficacy in Crohn's disease (CD) using rat models. Researchers established experimental CD in rats and analyzed microRNA expression profiles in colonic tissue. Key findings revealed significant downregulation of miR-147 and miR-205 in CD model rats compared to controls. Following HPM treatment, expression levels of both microRNAs were significantly upregulated, correlating with reduced colonic inflammation and tissue damage. The mechanism appears to involve miRNA-mediated downregulation of inflammatory mRNAs and negative regulation of pro-inflammatory signaling pathways, ultimately decreasing production of inflammatory cytokines. Clinical implications: This study provides molecular-level evidence supporting HPM as an effective intervention for CD management. The identified miRNA targets (miR-147 and miR-205) may serve as biomarkers for treatment response and suggest HPM works through epigenetic modulation of inflammatory pathways. Practitioners should consider HPM as an adjunctive therapy for IBD patients, particularly those seeking integrative approaches to reduce intestinal inflammation.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Mild moxibustion at ST25 and ST36 significantly reduced visceral hypersensitivity and intestinal inflammation in PI-IBS rats by increasing beneficial gut bacteria and modulating NLRP6 inflammasome signaling pathways.
📌 Moxibustion at ST25 reduced Crohn's disease intestinal inflammation by downregulating p53 protein expression and enhancing the SLC7A11/GSH/GPX4 pathway to prevent ferroptosis and lipid peroxidation.
📌 Mild moxibustion reduced ulcerative colitis inflammation in rats by activating the non-neuronal cholinergic system to release acetylcholine, which suppressed inflammatory markers through α7 nicotinic acetylcholine receptors.